课题基金 / 基金详情

THE DIAGNOSIS AND THE TREATMENT BY STEROIDS IN DIOPATHIC INTERSTITIAL PNEUMONIAS BASED ON THE TRANSBRONHIAL LUNG BIOPSY

THE DIAGNOSIS AND THE TREATMENT BY STEROIDS IN DIOPATHIC INTERSTITIAL PNEUMONIAS BASED ON THE TRANSBRONHIAL LUNG BIOPSY
基于经支气管肺活检的特发性间质性肺炎的诊断和类固醇治疗
批准号:
16590770
负责人:
WATANABE Kentaro
金额:
$2.08万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2007

项目摘要

项目成果

WATANABE Kentaro的其他基金

相似基金

相关文献

中文摘要
翻译
背景:近年来,越来越多的临床研究发表了合并肺纤维化和肺气肿(CPFE)。然而,颞叶呼吸功能下降与预后的关系尚不清楚。方法:本研究量化CPFE患者呼吸功能的年度变化,并比较CPFE患者呼吸功能变化与单纯特发性肺纤维化(IPF-alone)患者生存的关系。在我科出院时诊断为IPF的患者中,32例符合以下标准的患者被选为CPFE患者:1)潜伏性发作的呼吸困难,2)计算机断层扫描(CT)显示低衰减的圆形区域,提示肺气肿和弥漫网状混浊,以胸膜下为主,3)通气和/或弥散能力受损,4)没有已知的肺纤维化原因。55例符合以下标准的患者被单独归类为IPF: 1) CT扫描显示弥漫性网状混浊,胸膜下为主,但无肺气肿;2)符合CPFE患者的标准1、3和4。采用Kaplan-Meier法比较两组患者的生存率。在这些患者中,26例CPFE和33例ipf单独患者接受了至少一年的重复呼吸功能测试,以进一步分析呼吸功能和生存。结果:结果以中位数和范围表示。CPFE患者的基线肺活量(VC)高于单纯IPF患者(分别为90% [28%-132%]vs. 73% [28%-113%], p=0.018)。CPFE患者VC较基线年下降百分比明显低于单纯IPF患者(分别为-3.1%[-7.8%至+10.7%]和-6.1%[-33.7%至+1.4%],p<0.001)。CPFE患者的基线弥散能力(DL_co)明显低于单纯IPF患者(分别为46%[9%-75%]和59.5% [15%-103%],p=0.003)。CPFE患者的DL_co/VA(转移因子)基线值也低于单纯IPF患者(分别为53%[8%-82%]和76% [40%-126%],p<0.001)。然而,与单纯IPF患者相比,CPFE患者DL_co和DL_co/VA的年下降幅度较小(DL_co: -2.4%[-16.5%至8.1%]vs. -11.9%[-33.8%至+4.2%],p = 0064; DL_co/VA:-3.9%[-25.6%至+7.8%]vs.-3.4%[-28.0%至+15.3%],p = 0.464)。Kaplan-Meier分析显示,32例CPFE患者的生存期明显长于55例单纯ipf患者(p = 0.043)。结论:肺纤维化合并肺气肿患者肺体积保存良好是预测CPFE预后的重要因素。利用CT检测IPF患者并发肺气肿是避免错误预后的重要手段。作为CPFE的预后指标,通气和弥散能力降低的时间延迟有待进一步分析。少
英文摘要
Background: Recently, increasing numbers of clinical investigations of combined pulmonary fibrosis and emphysema (CPFE) have been published. However, the relationship between the temporal decrease of respiratory function and the prognosis is not well known.Methods: This study was performed to quantify the annual change in respiratory function of patients with CPFE and to compare the relationship between the change in respiratory function and survival in CPFE patients with that of patients with idiopathic pulmonary fibrosis alone (IPF-alone). Of patients who were diagnosed with IPF at discharge from our department, 32 who met the following criteria were selected as CPFE patients: 1) the presence of dyspnoea of insidious onset, 2) a computed tomography (CT) scan showing both round areas with low attenuation suggestive of emphysema and diffuse reticular opacities with sub-pleural predominance, 3) impaired ventilatory and/or diffusing capacity, and 4) an absence of known causes of pulmonar … More y fibrosis. Fifty-five patients who met the following criteria were categorized as having IPF alone: 1) a CT scan showing diffuse reticular opacities with sub-pleural predominance but no emphysema, 2) compliance with criteria 1, 3, and 4 as described for CPFE patients. The survival was compared between these 2 groups using Kaplan-Meier method. Of these patients, 26 CPFE and 33 IPF-alone patients who had undergone repeated respiratory function tests with at least one-year interval were selected for the further analysis of respiratory functions and survival.Results: Results are expressed as medians and ranges. The baseline vital capacity (VC) of CPFE patients was greater than that of patients with IPF alone (90% [28%-132%] vs. 73% [28%-113%], respectively, p=0.018). The annual % decrease in VC from the baseline was significantly less in CPFE patients than in those with IPF alone (-3.1% [-7.8% to +10.7%] vs. -6.1% [-33.7% to +1.4%], respectively, p<0.001). Baseline diffusing-capacity (DL_co) was significantly lower in patients with CPFE than in those with IPF alone (46% [9%-75%] vs. 59.5% [15%-103%], respectively, p=0.003). DL_co/VA (transfer factor) at baseline was also lower in CPFE patients than in those with IPF alone (53% [8%-82%) vs. 76% [40%-126%], respectively, p<0.001). However, the annual decreases in DL_co and DL_co/VA in CPFE patients were modest compared with those of patients with IPF alone (DL_co: -2.4% [-16.5% to 8.1%] vs. -11.9% [-33.8% to +4.2%], respectively, p = 0064; DL_co/VA:-3.9% [-25.6% to +7.8%] vs.-3.4% [-28.0% to +15.3%], respectively, p = 0.464). Survival of 32 CPFE patients was significantly longer than that of 55 patients with IPF-alone according to Kaplan-Meier analysis (p = 0.043).Conclusion : Well-preserved lung volume in combined pulmonary fibrosis and emphysema complicates prediction of the prognosis of CPFE. Detection of coexistent emphysema in IPF patients using CT is important to avoid making an erroneous prognosis. Delay of the temporal decrease of ventilatory and diffusing capacity needs to be further analyzed as a prognostic indicator of CPFE. Less
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
間質性肺炎の病態と治療 IIP_sの臨床診断
间质性肺炎的病理和治疗 IIP_s 的临床诊断
DOI: --
发表时间: 2006
期刊: 呼吸と循環 54・10
影响因子: --
作者: [吉村邦彦, 岸 一馬, 高宮有介, 守田美奈子, 吉田みつ子, 大松重宏, 渡辺 憲太朗, 渡辺 憲太朗, 渡辺 憲太朗, Kentaro Watanabe, Kentaro Watanabe, 渡辺 憲太朗, 渡辺憲太朗]
通讯作者: 渡辺憲太朗
NSIPの過去・現在・未来(掲載確定)
NSIP的过去、现在和未来(已确认发表)
DOI: --
发表时间: 2008
期刊: 呼吸と循環
影响因子: --
作者: [吉村邦彦, 岸 一馬, 高宮有介, 守田美奈子, 吉田みつ子, 大松重宏, 渡辺 憲太朗]
通讯作者: 渡辺 憲太朗
間質性肺炎における呼吸機能の再評価
间质性肺炎呼吸功能的重新评估
DOI: --
发表时间: 2007
期刊: THE LUNG perspectives 15
影响因子: --
作者: [吉村邦彦, 岸 一馬, 高宮有介, 守田美奈子, 吉田みつ子, 大松重宏, 渡辺 憲太朗, 渡辺 憲太朗]
通讯作者: 渡辺 憲太朗
特発性肺線維症:診断と治療の進歩.I.診断と病態. 6.呼吸機能検査
特发性肺纤维化:诊断和治疗进展 I. 诊断和发病机制 6. 呼吸功能检查。
DOI: --
发表时间: 2005
期刊: 日本内科学会雑誌 94・6
影响因子: --
作者: [星野友昭, 北里裕彦, 今岡治樹, 木下隆, 加藤誠也, 渡辺憲太朗, 相澤久道, 渡辺 憲太朗]
通讯作者: 渡辺 憲太朗
共 18 条
    Development of Work Knowledge Circulation Method for Service Fields
    Development of a Technology Selection Method of Process Observation and Modeling for Labor-Intensive Services
    Development of cathodoluminescence nanospectroscopy for the insulating nanostructures
    Meso-pelagic animal behavior study by animal borne camera and 3-D loggers
    • 批准号:
      14405027
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.96万
    • 财政年份:
      2002
    • 负责人:
      WATANABE Kentaro
    • 依托单位:
    海外基金